EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Envoy Medical, Inc (COCH) fair value: what the stock is really worth

As of Sep 30, 2026: fair value of Envoy Medical, Inc $0.13, price $0.68, upside -81.3%, quality 5 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US29415V1098

EM Envoy Medical, Inc logo Thin data Sep 27, 2026

Envoy Medical, Inc

COCH · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.1275 · Strongly overvalued (−81.3%)
!Quality 5/100
!Weak Growth (revenue 3y +0.6 %/yr)
!Negative equity (buybacks among others) · negative free cash flow
!Trails peers (1/5)
!Narrow moat 12/100
!Evidence only low, so the estimate is less certain
Watch Envoy Medical, Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$10.50 $0.3900 Fair Value $0.1275 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range $0.3900 – $10.50 · fair‑value band $0.1190 – $0.1360 · the $0.6811 price screens above the $0.1275 fair value. Dashed = 300-day average. As of Sep 27, 2026.

Follow Envoy Medical in your weekly email

Every Wednesday you see whether Envoy Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Envoy Medical, Inc., a hearing health company, provides medical technologies across the hearing loss spectrum. The company's medical technologies are designed to shift the paradigm within the hearing industry and bring providers and patients the hearing devices desire.

Show more

Envoy Medical, Inc., a hearing health company, provides medical technologies across the hearing loss spectrum. The company's medical technologies are designed to shift the paradigm within the hearing industry and bring providers and patients the hearing devices desire. It offers personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.

Stock analysis

Envoy Medical, Inc (COCH) currently trades at $0.6811, while our model-based Fair Value estimate is $0.1275, 81.3% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 3 models at a data quality of 96/100, which puts the evidence level at low.

Scenario range: $0.1190 (bear) to $0.1360 (bull), the price of $0.6811 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 5/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

Envoy Medical, Inc reported revenue of $241K in FY2025 versus $310K in FY2021, a compound −6.1%/yr. Reported net income was −$23.8M in FY2025.

Key figures

Market cap $70.9M · EPS (TTM) $−0.7600 · Dividend yield 3.2% · Return on assets (EBIT) −250% · Operating margin −10,920% · Revenue (TTM) $207K · Revenue growth (YoY) −34.6% · Free cash flow −$18.4M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).

What moves the price

The share trades about 57% below its 52-week high and 75% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −81%, COCH screens richer than that median.

Fair Value models

Bear $0.1190 Fair Value $0.1275 Bull $0.1360
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Gordon GGM $0.1600 $0.1800 $0.1900 67
DDM Multi-Stage $0.1600 $0.1900 $0.2300 65
All 2 models by family
Dividend Discount
Gordon GGM $0.1600 $0.1800 $0.1900 67
DDM Multi-Stage $0.1600 $0.1900 $0.2300 65

Open the full fair value analysis →

Notify me when COCH reaches fair value

Put COCH on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 5/100

Of which business quality 11 · Market factors (momentum, volatility) 20

Profitability 0
Margins and returns on capital today
Quality Growth 19
Are margins and returns improving?
Cashflow 6
Earnings quality: real cash, not paper profit
Fin. Strength 33
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 33
Price trend over the last 3–12 months (market factor)
52W Momentum 21
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 6/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+7.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2,216.5% (2021) → −9,240.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

COCH screens overvalued: fair value 81% below the price. Compare with Abbott Laboratories, →

Compare Envoy Medical, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 354 stocks

Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 5 · Bottom 25%
Fair Value upside −81.3% · Bottom 25%
Profitability
Return on equity (TTM) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −86.5% · Bottom 25%
Growth and dividend
Revenue growth −34.6% · Bottom 25%
Dividend yield (TTM) 3.2% · Above median
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 4
FUTURE (revenue growth)0 · sector 31
PAST (return on equity)0 · sector 8
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)65 · sector 37

VALUE 0: the price sits above our fair-value range.

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $101.29 $74.79 −26%
Medtronic plc MDT $87.09 $65.61 −25%
Stryker Corporation SYK $278.77 $306.65 +10%
Boston Scientific Corporation BSX $43.92 $48.31 +10%
Edwards Lifesciences Corporation EW $86.29 $81.94 −5%
Siemens Healthineers AG SHL €37.79 €35.19 −7%
DexCom, Inc DXCM $86.68 $95.35 +10%
GE HealthCare Technologies Inc GEHC $66.63 $70.37 +6%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥153.86 ¥169.25 +10%
Koninklijke Philips N.V PHIA €21.87 €15.23 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Envoy Medical, Inc · Fair Value
$0.1275 −81%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Envoy Medical, Inc Fair Value". https://www.fairvalue-calculator.com/stock/COCH

Frequently asked questions

Is Envoy Medical, Inc (COCH) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.1275 versus a price of $0.6811, about −81% upside (overvalued).
What is the fair value of COCH?
Our model-based fair value for Envoy Medical, Inc is $0.1275 (as of Sep 27, 2026), built from audited fundamentals. The current price: $0.6811.
What is the quality score of COCH?
Envoy Medical, Inc has a Quality Score of 5/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Envoy Medical, Inc (COCH)?
Our model-based price target is the fair value of $0.1275 (as of Sep 27, 2026) from 2 valuation models. Cautious scenario $0.1190, optimistic scenario $0.1360. It is a calculation from audited fundamentals, not an analyst target.
What is the Envoy Medical, Inc stock forecast for 2026?
Our models put fair value at $0.1275, about −81% upside versus a price of $0.6811 (overvalued). Cautious scenario $0.1190, optimistic scenario $0.1360. The calculation is refreshed regularly with new filings.
What is the revenue of Envoy Medical, Inc (COCH)?
Envoy Medical, Inc reported trailing-twelve-month revenue of about $207K (latest available figure, as of Sep 27, 2026).
Does Envoy Medical, Inc pay a dividend?
Envoy Medical, Inc currently shows a dividend yield of about 3.23% relative to its recent price (as of Sep 27, 2026).
What is the intrinsic value of Envoy Medical, Inc (COCH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Envoy Medical, Inc it is $0.1275 per share (as of Sep 27, 2026), against a price of $0.6811. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Envoy Medical, Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, COCH trades above its calculated fair value: price $0.6811, fair value $0.1275, a gap of about −81% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of COCH?
No. The price is what the market pays today ($0.6811); the fair value is what the company's own numbers justify ($0.1275). For Envoy Medical, Inc the two are $0.5536 per share apart. That gap is exactly why we show both numbers side by side.
How much is Envoy Medical, Inc worth?
The market values Envoy Medical, Inc at about $70.9M (market capitalisation, as of Sep 27, 2026). Per share that is $0.6811; our models calculate a fair value of $0.1275 per share.
What do the bullish and bearish scenarios say about COCH?
Our models span a range for Envoy Medical, Inc: cautious scenario $0.1190, base $0.1275, optimistic $0.1360 per share (as of Sep 27, 2026, price $0.6811). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Envoy Medical, Inc (COCH)?
Balance-sheet figures for Envoy Medical, Inc (as of Sep 27, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 5/100, which measures business quality independently of the share price.
How far is COCH from its 52-week high?
Envoy Medical, Inc trades at $0.6811, about 57% below its 52-week high of $1.59 and 75% above the low of $0.3900 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of $0.1275 is for.
Which stocks are comparable to Envoy Medical, Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Envoy Medical, Inc stock attractive at the current price?
The data as of Sep 27, 2026: price $0.6811, calculated fair value $0.1275 (−81%), Quality Score 5/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of COCH calculated?
We run Envoy Medical, Inc through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.1275, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. Envoy Medical, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Envoy Medical, Inc (COCH)?
The closing price on Sep 30, 2026 was $0.6811. Our model-based fair value is $0.1275, about −81% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Envoy Medical, Inc right now?
The price sits above even our optimistic bull case ($0.1360). The favourable scenario is already priced in. Weak quality (5/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. The models converge in a tight band ($0.1190 to $0.1360), unusually little disagreement for a valuation.

Key figures of Envoy Medical, Inc

How large is the market capitalisation of Envoy Medical, Inc (COCH)?
The market capitalisation of Envoy Medical, Inc is $70.9M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Envoy Medical, Inc (COCH)?
Earnings per share at Envoy Medical, Inc are $−0.7600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Envoy Medical, Inc (COCH)?
The dividend yield of Envoy Medical, Inc is 3.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the EBIT return on assets of Envoy Medical, Inc (COCH)?
On an EBIT basis the return on assets of Envoy Medical, Inc is −250% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Envoy Medical, Inc (COCH)?
The operating margin of Envoy Medical, Inc is −10,920% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Envoy Medical, Inc (COCH)?
Revenue at Envoy Medical, Inc is growing −34.6% versus a year earlier (3y avg +0.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Envoy Medical, Inc (COCH) generate?
The free cash flow of Envoy Medical, Inc is −$18.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Envoy Medical, Inc (COCH) hold?
Envoy Medical, Inc holds more cash than debt, $2.8M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Envoy Medical, Inc in the live analysis

One click puts Envoy Medical, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.